RHOEN-KLINIKUM AG

Latest Results (22.01.2026):

RHOEN-KLINIKUM AG — Q1 2024: The Group reported stronger first‑quarter operating and net results versus Q1 2023 driven by higher patient volumes and higher state base rates. Revenues rose to €382.8m (+5.9%), EBITDA to €25.2m (+12.0%), EBIT to €10.0m (+61.3%) and consolidated profit to €11.1m (+73.4%). Total patient cases increased 2.6% to 234,151 and earnings per share were €0.16 (undiluted).

Key financials

Revenues €382.8m (+€21.3m / +5.9%), EBITDA €25.2m, EBIT €10.0m, EBT €13.3m (+95.6%), consolidated profit €11.1m (+73.4%). Other income rose to €72.9m (19.1% of revenues).

Patient volumes

Total cases for Q1 2024 were 234,151 (up 5,962 cases / +2.6% vs. Q1 2023). Outpatient attendances at acute hospitals +5.2%; rehab and other facilities +4.5%.

Costs and margins

Material expenses increased by €11.7m (cost‑of‑materials ratio 34.4% vs 33.2% a year ago). Employee benefits rose €18.0m to €257.1m (personnel expense ratio 67.2% vs 66.1%) reflecting higher headcount and wage increases. Other expenses were broadly stable (+€0.6m).

Other income & energy relief

Other income increased by €11.3m, mainly from ancillary activities (higher drug/cytostatic sales and training‑centre funding) and €3.5m reimbursements from the Health Fund to offset higher energy costs.

Balance sheet & liquidity

Total assets €1,811.6m; shareholders’ equity €1,291.7m (71.3% of balance sheet). Cash and cash equivalents €225.6m. Non‑current assets €974.5m.

Employees

Workforce at 31 March 2024: 18,324 employees (up 78 / +0.4% vs 31 Dec 2023).

Sector environment & outlook

The company highlights the planned German hospital reform (capacity‑based remuneration, service groups, cross‑sector care, transformation fund) and the Hospital Transparency Act as dominant sector drivers — presenting both cost pressures and strategic opportunities (campus approach, ambulantisation, new services) for RHOEN‑KLINIKUM AG in 2024.